Merck & Co.

Merck and Ridgeback’s COVID-19 pill fails to prevent infection within households

Merck – known as MSD outside the US and Canada – has reported that its COVID-19 pill, jointly developed with Ridgeback, did not significantly reduce the risk of infections in those living ... Robert Davis, chief executive officer and chairman of Merck

Merck reports positive results for Keytruda combination in phase 3 gastric cancer trial

Merck &Co (Merck) – known as MSD outside the US and Canada – has reported positive results from a phase 3 study of its anti-PD-1 therapy Keytruda (pembrolizumab) in combination with ... Dr Scot Ebbinghaus, vice president, clinical research, Merck

AstraZeneca and MSD report final overall survival results from prostate cancer study

AstraZeneca and MSD – known as Merck &Co in the US and Canada – have reported final overall survival results from a phase 3 trial of a Lynparza (olaparib) combination in metastatic

US health department proposes three new models to help lower cost of drugs

monthly $2 fixed co-payment for commonly used generic drugs for chronic conditions, such as high blood pressure.

MSD’s Keytruda plus chemotherapy approved in Scotland for advanced cervical cancer

MSD’s – known as Merck &Co in the US and Canada – Keytruda (pembrolizumab) in combination with chemotherapy has been recommended by the Scottish Medicines Consortium (SMC) for advanced cervical cancer. ... MSD is delighted that the SMC will now

[ Previous 5 results ] 2 3 4 5 6 7 8 9 10 11 [ Next 5 results ]